ACE and metabolic dysfunction-associated steatotic liver disease: Among the study groups we enrolled 35 patients affected by arterial hypertension treated with ACE-inhibitors, calcium antagonists, or non-selective beta blocker: 13 in the NAFLD wild type control group, 8 in the NAFLD treated wild type, and 14 in the NAFLD treated mutated one, respectively.